Based on these findings, the repurposing of riluzole (a sodium channel and NMDA receptor blocker and BK channel activator), is suggested as a treatment for epilepsy caused by LGI1, KCNA1 or KCNA2 mutations [129]. This evidence concerns the gene KCNA1 and epilepsy.